Key Takeaways:
-
Bloom’s lead candidate, BL-001, comprises two microbes that replicate the antiepileptic effects of the ketogenic diet.
Bloom Science, Inc. is advancing a pipeline of live biotherapeutics derived from gut commensal microbes to alter key brain-gut microbiome interactions in a bid to treat rare neurological disorders.
The US firm was founded in 2018 by CEO Christopher Reyes, a biophysicist by training who started his entrepreneurial career...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?